Background
Bisphosphonates inhibit osteoclastic bone resorption and are used in malignant disease to treat hypercalcaemia, reduce skeletal morbidity associated with bone metastases and, less often, in the adjuvant setting to delay the development of bone metastases. As there are economic implications for the widespread use of these drugs, it is essential that their use is evidence based. 
Objectives

Data extraction
All studies were assessed for inclusion then data extracted by two independent reviewers. Consensus was reached, with a third reviewer's decision being final. Studies were graded according to blinding and allocation concealment.
Data synthesis
Where possible, overall event rates were calculated by meta-analysis and pooled odds ratios (OR) given with 95% confidence intervals (CIs). Where data could not be combined, studies were reported individually and proportions compared using chisquared analysis. Cost and cost-effectiveness were assessed by a decision analytic model comparing different bisphosphonate regimens for the treatment of hypercalcaemia; Markov models were employed to evaluate the use of bisphosphonates to prevent SRE in patients with breast cancer and multiple myeloma. 
Skeletal morbidity review
Primary analysis
On meta-analysis, bisphosphonates, compared with placebo, significantly reduced the OR for vertebral fractures, non-vertebral fractures, combined fractures, radiotherapy and hypercalcaemia but not 
Time to first SRE
Bisphosphonates (intravenous pamidronate and intravenous zoledronate) significantly increase the time to first SRE. The evidence for oral clodronate is conflicting.
Sub-analysis over time
The OR for radiotherapy was significantly reduced at all time points. Orthopaedic surgery showed a progressive reduction in OR with narrowing of the CI, reaching significance at 24 months. For hypercalcaemia, the reduction in the OR was significant at all time points except 18-24 months.
Sub-analysis of disease groups
Two results contrasted strongly with the primary analysis. Vertebral fractures were not significantly reduced in patients with breast cancer, OR (95% CI) 0.870 (0.656 to 1.154), p = 0.334. Hypercalcaemia was not significantly reduced in patients with myeloma, OR (95% CI) 0.968 (0.687 to 1.365), p = 0.852. 
Sub-analysis of drugs
Sub-analysis of route
Oral bisphosphonates significantly reduced the OR for vertebral fractures and non-vertebral fractures. Intravenous bisphosphonates significantly reduced the OR for all outcomes except spinal cord compression.
Survival
There was no survival benefit.
Adjuvant review
Clodronate significantly reduces the number of patients with primary operable breast cancer developing bone metastases. This benefit was not maintained once regular administration had been discontinued. Two trials reported significant survival advantages in the treated groups. These findings were not seen in trials of patients with advanced disease.
Toxicity
Bisphosphonates are well tolerated with a low incidence of side-effects
Economic review
Hypercalcaemia
Drugs with the longest cumulative duration of normocalcaemia were most cost-effective. Zoledronate 4 mg was the most costly but most costeffective treatment (approximately £22,900 per life year gained). The estimates of cost-effectiveness were sensitive to amount of time in hospital.
Skeletal morbidity
The overall cost of bisphosphonate therapy to prevent an SRE was estimated at £250 and £1500 per event for patients with breast cancer and multiple myeloma, respectively. The model suggested that bisphosphonate treatment is sometimes cost-saving in breast cancer patients where fractures are prevented. The models were sensitive to the probability of averting an SRE, the unit cost of an SRE and the price of bisphosphonate treatment. 2004; Vol. 8: No. 4 (Executive summary)
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Conclusions
Bisphosphonates normalise serum calcium in >70% of patients with hypercalcaemia of malignancy within 2-6 days; pamidronate doubles the time to relapse compared with nonaminobisphosphonates. They significantly reduce SREs and delay the time to first SRE in patients with bony metastatic breast cancer and multiple myeloma. Benefit is seen at different time points for different SREs. Bisphosphonates do not affect survival. The current evidence is strongest for the efficacy of pamidronate and for the intravenous over the oral route of administration. In primary operable breast cancer, oral clodronate reduces the number of patients developing bone metastases.
Implications for healthcare
Bisphosphonate therapy appears cost-effective in the treatment of hypercalcaemia and for the prevention of skeletal morbidity, particularly for patients with breast cancer. The economic evidence reviewed was of limited quality, therefore any conclusions based on this evidence need to be interpreted with caution.
Recommendations for research
Hypercalcaemia G RCT of bisphosphonate maintenance therapy to delay time to relapse in patients following first episode of hypercalcaemia G trial of parathyroid hormone-related protein (PTHrP) blocker in combination with bisphosphonate in patients with very high levels of PTHrP.
Skeletal morbidity
G RCT using bisphosphonates for prevention of skeletal morbidity in patients with prostate cancer metastatic to bone G trials to determine the optimum time to commence bisphosphonate therapy: at diagnosis of asymptomatic bone metastases or at first SRE? G trial to compare efficacy of oral versus intravenous bisphosphonate G a study to determine current clinical practice with respect to bisphosphonate use in UK oncology centres.
Adjuvant use
G extended use of bisphosphonates (>3 years) for primary prevention of bone metastases from breast cancer G adjuvant use of bisphosphonates in patients with prostate cancer at high risk of developing bone metastases.
Economic analyses
The evidence base for estimating cost and costeffectiveness is limited. Further cost and quality of life data are required to identify cost-effectiveness associated with reductions in SREs and delayed time to first SRE. Data on cumulative length of stay and response to successive treatments for patients with hypercalcaemia are needed.
